nature portfolio

Corresponding author(s):	François Moreau-Gaudry / Aurélie Bedel
Last updated by author(s):	May 31, 2023

Reporting Summary

Nature Portfolio wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Portfolio policies, see our Editorial Policies and the Editorial Policy Checklist.

Sta	Statistics				
For all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.					
n/a	Confirmed				
	🗶 The exact	sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement			
	🗶 A stateme	tement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly			
	The statistical test(s) used AND whether they are one- or two-sided Only common tests should be described solely by name; describe more complex techniques in the Methods section.				
X	A descript	A description of all covariates tested			
x	A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons				
	A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)				
	For null hypothesis testing, the test statistic (e.g. <i>F</i> , <i>t</i> , <i>r</i>) with confidence intervals, effect sizes, degrees of freedom and <i>P</i> value noted <i>Give P values as exact values whenever suitable.</i>				
x	For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings				
x	For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes				
$ \mathbf{x} $ Estimates of effect sizes (e.g. Cohen's d , Pearson's r), indicating how they were calculated					
Our web collection on <u>statistics for biologists</u> contains articles on many of the points above.					
Software and code					
Policy information about <u>availability of computer code</u>					
Dat	a collection	N/A			
Data analysis Grapl		Graph Pad Prism6 software			
For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Portfolio guidelines for submitting code & software for further information.					

Data

Policy information about availability of data

All manuscripts must include a <u>data availability statement</u>. This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A description of any restrictions on data availability
- For clinical datasets or third party data, please ensure that the statement adheres to our policy

OK

Human research participants				
Policy information about studies involving human research participants and Sex and Gender in Research.				
Reporting on sex an	nd gender	N/A		
Population characte	eristics	Human CD34+ HSPCs were isolated from one cord blood of a healthy donor from Bagatelle Hospital, Talence, France		
Recruitment		according to ethical standards and with mother's informed consent		
Ethics oversight		cord blood sample was obtained after maternal informed consent according to procedures approved by the Bagatelle Hospital		
Note that full informa	tion on the appro	oval of the study protocol must also be provided in the manuscript.		
Field-spe	cific re	porting		
Please select the or	ne below that is	the best fit for your research. If you are not sure, read the appropriate sections before making your selection.		
x Life sciences	Ве	ehavioural & social sciences		
For a reference copy of t	he document with a	Il sections, see <u>nature.com/documents/nr-reporting-summary-flat.pdf</u>		
Life scier	ices stu	ıdy design		
All studies must dis	close on these	points even when the disclosure is negative.		
Sample size	No calculation, a	at least three independant experiments		
Data exclusions	No data were ex	cluded		
Replication	at least three in	dependant experiments		
Randomization	not relevant			
Blinding	not relevant			
	(
Reportin	g for sp	ecific materials, systems and methods		
We require information	on from authors a	bout some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.		
Materials & exp	perimental sy	ystems Methods		
n/a Involved in th	n/a Involved in the study n/a Involved in the study			
Antibodies				
Eukaryotic cell lines				
Palaeontology and archaeology MRI-based neuroimaging Animals and other organisms				
X Clinical data				
Dual use research of concern				
Antibodies				

CD34 antibody clone 561 Biolegend, USA to check HSPC purity

lot B2044487, Biolegend website

Antibodies used

Validation

Flow Cytometry

Plots

Confirm that:

- The axis labels state the marker and fluorochrome used (e.g. CD4-FITC).
- The axis scales are clearly visible. Include numbers along axes only for bottom left plot of group (a 'group' is an analysis of identical markers).
- | All plots are contour plots with outliers or pseudocolor plots.
- 🗶 A numerical value for number of cells or percentage (with statistics) is provided.

Methodology

Sample preparation	CD34+ were isolated from cord blood after ficoll isolation by magnetic cell sorting, FAMRed fibroblasts are spontaneoulsy fluorescent by porphyrins accumulation
Instrument	BC accuri FACS
Software	BD accuri C6 plus software
Cell population abundance	purity of CD34+ is validated when > 90%
Gating strategy	FSC/SSC gates